Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – What’s Next?

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) gapped up before the market opened on Monday . The stock had previously closed at $1.49, but opened at $1.7150. Autolus Therapeutics shares last traded at $2.0150, with a volume of 3,178,453 shares changing hands.

Analyst Ratings Changes

Several brokerages recently issued reports on AUTL. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Wall Street Zen raised shares of Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Autolus Therapeutics Stock Performance

The company has a 50-day moving average price of $1.57 and a 200-day moving average price of $1.52. The firm has a market capitalization of $501.70 million, a P/E ratio of -1.74 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The firm had revenue of $26.22 million for the quarter, compared to analyst estimates of $26.27 million. Equities analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.95 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Schroder Investment Management Group raised its stake in shares of Autolus Therapeutics by 133.7% in the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock valued at $13,409,000 after purchasing an additional 4,824,763 shares during the period. Mak Capital One LLC boosted its holdings in shares of Autolus Therapeutics by 15.3% in the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after buying an additional 3,987,727 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Autolus Therapeutics by 30.0% in the third quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after buying an additional 3,600,000 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock worth $3,308,000 after purchasing an additional 1,054,458 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at about $639,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.